These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro. Weigand M; Hantel P; Kreienberg R; Waltenberger J Angiogenesis; 2005; 8(3):197-204. PubMed ID: 16328160 [TBL] [Abstract][Full Text] [Related]
3. Proliferation of endothelial and tumor epithelial cells by progestin-induced vascular endothelial growth factor from human breast cancer cells: paracrine and autocrine effects. Liang Y; Hyder SM Endocrinology; 2005 Aug; 146(8):3632-41. PubMed ID: 15845615 [TBL] [Abstract][Full Text] [Related]
4. The expression of VEGF receptor genes is concurrently influenced by epigenetic gene silencing of the genes and VEGF activation. Kim JY; Hwang JH; Zhou W; Shin J; Noh SM; Song IS; Kim JY; Lee SH; Kim J Epigenetics; 2009 Jul; 4(5):313-21. PubMed ID: 19633424 [TBL] [Abstract][Full Text] [Related]
5. Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling. Zhou X; Yue GG; Liu M; Zuo Z; Lee JK; Li M; Tsui SK; Fung KP; Sun H; Pu J; Lau CB Oncotarget; 2016 Dec; 7(50):82820-82835. PubMed ID: 27756875 [TBL] [Abstract][Full Text] [Related]
6. Selective inhibition of vascular endothelial growth factor receptor-2 (VEGFR-2) identifies a central role for VEGFR-2 in human aortic endothelial cell responses to VEGF. Endo A; Fukuhara S; Masuda M; Ohmori T; Mochizuki N J Recept Signal Transduct Res; 2003; 23(2-3):239-54. PubMed ID: 14626450 [TBL] [Abstract][Full Text] [Related]
7. Increased angiogenesis and expression of vascular endothelial growth factor during scarless repair. Colwell AS; Beanes SR; Soo C; Dang C; Ting K; Longaker MT; Atkinson JB; Lorenz HP Plast Reconstr Surg; 2005 Jan; 115(1):204-12. PubMed ID: 15622252 [TBL] [Abstract][Full Text] [Related]
10. Src kinase becomes preferentially associated with the VEGFR, KDR/Flk-1, following VEGF stimulation of vascular endothelial cells. Chou MT; Wang J; Fujita DJ BMC Biochem; 2002 Dec; 3():32. PubMed ID: 12509223 [TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy. Shinkaruk S; Bayle M; Laïn G; Déléris G Curr Med Chem Anticancer Agents; 2003 Mar; 3(2):95-117. PubMed ID: 12678905 [TBL] [Abstract][Full Text] [Related]
12. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Dias S; Hattori K; Heissig B; Zhu Z; Wu Y; Witte L; Hicklin DJ; Tateno M; Bohlen P; Moore MA; Rafii S Proc Natl Acad Sci U S A; 2001 Sep; 98(19):10857-62. PubMed ID: 11553814 [TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor receptor-2: its unique signaling and specific ligand, VEGF-E. Shibuya M Cancer Sci; 2003 Sep; 94(9):751-6. PubMed ID: 12967471 [TBL] [Abstract][Full Text] [Related]